DUBLIN – Bavarian Nordic A/S picked up a second bulk supply order for its Imvamune smallpox vaccine from the U.S. government, a $100 million deal that comes on top of the $133 million contract it secured last year. It's further evidence that the transition from liquid-frozen formulation to longer-lasting freeze-dried vaccine is under way.